Literature DB >> 22349725

Evaluation of the duration of the antibiotic prophylaxis in paediatric postoperative heart surgery patients.

Pablo Álvarez1, Carolina Fuentes, Nuria García, Vincent Modesto.   

Abstract

The ideal duration of postoperative antibiotic prophylaxis in heart surgery is unknown. The most recent guidelines recommend a decrease in prophylaxis time to decrease the emergence of multiresistant germs. However, compliance with these recommendations is scant. Our aim was to determine whether a decrease in prophylaxis time entails an increase in the infection rate. A retrospective study was performed between September 2003 and March 2006, including all patients of ages between 1 day and 14 years who were admitted to the intensive care unit after heart surgery. Patients being treated for an infection at the time of surgery were excluded. The appearance of nosocomial infection, localisation, and the causative agent, if isolated, were included; demographic and clinical analytical variables, duration and type of antibiotic prophylaxis, and duration of other invasive devices were also included. Standard analysis and multivariable logistical regression were performed. 194 patients were included in the study. The median duration of antibiotic prophylaxis was 72 h (range 24 to 176), with the most-used prophylaxis regimen being second-generation cephalosporins plus aminoglycosides. The incidence of nosocomial infection, mainly bacteraemia, was 11.9%. The type of antibiotic therapy used for prophylaxis did not affect the incidence of infection. In the multivariable logistical regression, only prolongation of antibiotic prophylaxis >48 h, central venous access maintenance time, and intubation increased the infection rate. The suspension of antibiotic prophylaxis in the 48 h after surgery in pediatric patients undergoing heart surgery does not increase the incidence of nosocomial infection. According to our results, prolongation of prophylaxis >48 h increases the infection rate.

Entities:  

Mesh:

Year:  2012        PMID: 22349725     DOI: 10.1007/s00246-012-0202-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  7 in total

Review 1.  Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.

Authors:  Dale W Bratzler; Peter M Houck
Journal:  Am J Surg       Date:  2005-04       Impact factor: 2.565

2.  The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration.

Authors:  Fred H Edwards; Richard M Engelman; Peter Houck; David M Shahian; Charles R Bridges
Journal:  Ann Thorac Surg       Date:  2006-01       Impact factor: 4.330

Review 3.  The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice.

Authors:  Richard Engelman; David Shahian; Richard Shemin; T Sloane Guy; Dale Bratzler; Fred Edwards; Marshall Jacobs; Hiran Fernando; Charles Bridges
Journal:  Ann Thorac Surg       Date:  2007-04       Impact factor: 4.330

4.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

5.  [Nosocomial infections in pediatric patients following cardiac surgery].

Authors:  M T Guardia Camí; I Jordan García; M Urrea Ayala
Journal:  An Pediatr (Barc)       Date:  2008-07       Impact factor: 1.500

6.  Adherence to international antimicrobial prophylaxis guidelines in cardiac surgery: a Jordanian study demonstrates need for quality improvement.

Authors:  Nairooz H Al-Momany; Amal G Al-Bakri; Zeid M Makahleh; Mayyada M B Wazaify
Journal:  J Manag Care Pharm       Date:  2009-04

7.  Effects of controlled perioperative antimicrobial prophylaxis on infectious outcomes in pediatric cardiac surgery.

Authors:  Yuko Kato; Nobuaki Shime; Satoru Hashimoto; Mayuko Nomura; Yoko Okayama; Masaaki Yamagishi; Naohisa Fujita
Journal:  Crit Care Med       Date:  2007-07       Impact factor: 7.598

  7 in total
  5 in total

1.  Peri-Operative Prophylaxis in Patients of Neonatal and Pediatric Age Subjected to Cardiac and Thoracic Surgery: A RAND/UCLA Appropriateness Method Consensus Study.

Authors:  Sonia Bianchini; Laura Nicoletti; Sara Monaco; Erika Rigotti; Agnese Corbelli; Annamaria Colombari; Cinzia Auriti; Caterina Caminiti; Giorgio Conti; Maia De Luca; Daniele Donà; Luisa Galli; Silvia Garazzino; Alessandro Inserra; Stefania La Grutta; Laura Lancella; Mario Lima; Andrea Lo Vecchio; Gloria Pelizzo; Nicola Petrosillo; Giorgio Piacentini; Carlo Pietrasanta; Nicola Principi; Matteo Puntoni; Alessandro Simonini; Simonetta Tesoro; Elisabetta Venturini; Annamaria Staiano; Fabio Caramelli; Gaetano Domenico Gargiulo; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2022-04-21

2.  Implementing a standardized perioperative antibiotic prophylaxis protocol for neonates undergoing cardiac surgery.

Authors:  Meghan T Murray; Rozelle Corda; Rebecca Turcotte; Emile Bacha; Lisa Saiman; Ganga Krishnamurthy
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

Review 3.  Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update.

Authors:  Despoina Gkentzi; Gabriel Dimitriou
Journal:  Curr Pediatr Rev       Date:  2019

4.  Procalcitonin to stop antibiotics after cardiovascular surgery in a pediatric intensive care unit-The PROSACAB study.

Authors:  Sara Bobillo-Perez; Anna Sole-Ribalta; Monica Balaguer; Elisabeth Esteban; Monica Girona-Alarcon; Lluisa Hernandez-Platero; Susana Segura; Aida Felipe; Francisco Jose Cambra; Cristian Launes; Iolanda Jordan
Journal:  PLoS One       Date:  2019-09-18       Impact factor: 3.240

5.  Safety of a 2-Day Antibiotic Regimen After Delayed Chest Closure Post Pediatric Cardiac Surgery.

Authors:  Joseph Philip; Christian Kegg; Dalia Lopez-Colon; Brian J Kelly; Robert M Lawrence; Matthew A Robinson; Ravi S Samraj; Mark S Bleiweis
Journal:  J Intensive Care Med       Date:  2018-08-08       Impact factor: 2.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.